ORTHOSON key facts
as of Oct 2026- Developer of an injectable bio-structural gel implant system designed to restore disc function and relieve back pain from degeneration.
- ORTHOSON is valued at approximately $31.0M as of Oct 2026 (last reported valuation).
- It has raised $18.9M; the latest was Later Stage VC ($3.5M) in Oct 2025.
- Notable investors include Innovate UK, University of Oxford, Yonghua Capital, Perivoli Innovations, Anjost Investment — 12 tracked in total.
- Status: Privately Held (backing).
ORTHOSON's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch ORTHOSON: the Monday email on marks, rounds and moves
ORTHOSON funding rounds
No funding rounds for ORTHOSON are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs ORTHOSON
12+ORTHOSON valuation
ORTHOSON's last reported valuation was $31 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
ORTHOSON investors
12 investors are on record for ORTHOSON, including Innovate UK, University of Oxford, Yonghua Capital and Perivoli Innovations.
About ORTHOSON
Developer of an injectable bio-structural gel implant system designed to restore disc function and relieve back pain from degeneration. The company offers a micro-invasive implant that is injected into the disc, forms a supportive scaffold, restores mechanical properties, and suppresses degeneration, enabling patients with degenerative disc disease to achieve pain relief and improved spinal stability.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2015
- Employees
- 14
- Website
- orthoson.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.